Pfizer settles Rezulin product liability litigation
Executive Summary
Pfizer has settled thousands of personal injury claims alleging the diabetes drug Rezulin (troglitazone) caused liver damage. The number of claims and the size of the settlement are confidential. However, Bloomberg reported that the company is paying $750 million to settle 35,000 claims. The company had set aside $975 million in 2003 for the litigation. Pfizer said the multidistrict litigation is now resolved and there are only a handful of cases remaining in state court, which it expects will be dismissed. Pfizer withdrew Rezulin from the market in 2000 after people taking the drug experienced liver failure
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.